Fig. 7From: Clinical impact of 99mTc-MAA SPECT/CT-based personalized predictive dosimetry in selective internal radiotherapy: a real-life single-center experience in unresectable HCC patientsDot plot of perfused fraction of the total tumor volume according to perfused tumor adsorbed dose and tumor response evaluated following mRECIST (target) criteria at 3 months, in patients from group B with PET-CT-based dosimetryBack to article page